| Yazarlar |
Nazan Dalgic
University of Health Sciences, Turkey |
|
Ayse Sahin
University of Health Sciences, Turkey |
|
Selda Hancerli Torun
İstanbul Tıp Fakültesi, Turkey |
|
Ozge Kaba
İstanbul Tıp Fakültesi, Turkey |
|
Pinar Onal
İstanbul University-Cerrahpaşa Cerrahpaşa Faculty of Medicine, Turkey |
Doç. Dr. Ayşe YILMAZ
Kastamonu Üniversitesi, Türkiye |
|
Ozden Turel
Bezmiâlem Vakıf Üniversitesi, Turkey |
|
Belma Yasar
University of Health Sciences, Turkey |
|
Manolya Kara
İstanbul Tıp Fakültesi, Turkey |
|
Deniz Aygun
İstanbul University-Cerrahpaşa Cerrahpaşa Faculty of Medicine, Turkey |
|
Ayse Kilinc
İstanbul University-Cerrahpaşa Cerrahpaşa Faculty of Medicine, Turkey |
|
Selim Oncel
Kocaeli Üniversitesi, Turkey |
|
Burcu Bursal Duramaz
Bezmiâlem Vakıf Üniversitesi, Turkey |
|
Nafiye Urganci
University of Health Sciences, Turkey |
|
Ayper Somer
İstanbul Tıp Fakültesi, Turkey |
|
Haluk Cokugras
İstanbul University-Cerrahpaşa Cerrahpaşa Faculty of Medicine, Turkey |
|
Emin Sami Arisoy
Kocaeli Üniversitesi, Turkey |
| Özet |
| Objective This study aimed to investigate the frequency of latent and active tuberculosis (TB) in pediatric patients receiving anti-tumor necrosis factor (TNF)-α therapy. Methods Patients younger than 18 years with various inflammatory diseases and treated with anti-TNF-α agents in the past five years were included in the study. The patients' ages, follow-ups, medications received, clinical and laboratory findings, and treatments applied were recorded retrospectively. Results Of the 160 patients included in the study, 78 (48.8%) were girls. The mean age was 139.54 ± 48.74 (30-226) months. Sixty (37.5%) patients had inflammatory eye disease, 55 (34.4%) had rheumatologic and autoimmune disease, and 45 (28.1%) had inflammatory bowel disease. As anti-TNF-α treatment, 67 (41.9%) patients received adalimumab, 50 (31.2%) received infliximab, and 43 (26.9%) received etanercept. As a result of TB screening performed prior to the treatment, 44 (25.4%) patients were started on isoniazid treatment with the diagnosis of latent TB. During follow-up, latent TB infection was detected in 16 (9.2%) patients and isoniazid treatment was started. The time to develop latent TB under anti-TNF-α treatment ranged from 3 to 28 months. During the treatment, active TB infection developed in two (1.2%) patients and anti-TB treatment was initiated. Conclusion It is of vital importance to evaluate patients receiving, or planned to receive, anti-TNF-α treatment, for TB infection and to initiate appropriate treatments if latent or active TB infection is identified. |
| Anahtar Kelimeler |
| children | tuberculosis | tumor necrosis factor |
| Makale Türü | Özgün Makale |
| Makale Alt Türü | SCOPUS dergilerinde yayımlanan tam makale |
| Dergi Adı | Journal of Pediatric Infectious Diseases |
| Dergi ISSN | 1305-7707 |
| Makale Dili | İngilizce |
| Basım Tarihi | 03-2021 |
| Cilt No | 17 |
| Sayı | 2 |
| Sayfalar | 90 / 97 |
| Doi Numarası | 10.1055/s-0042-1743195 |
| Atıf Sayıları |
